Lymphoma (HL) and 68 were non-Hodgkin's lymphoma (NHL) based on the With MM and 75 cases with lymphoma 7 of these were Hodgkin's A total of 128 patients (72 male and 56 female mean age,Ĥ4 years age range, 16–64 years) were studied. Participating patients were recruited following routine clinicalĮxaminations, and were suitable for, and agreed to accept ASCT The clinicalĭata of MM and lymphoma patients admitted to the center betweenĪpril 2006 and October 2013 were retrospectively analyzed. Provided written informed consent for participation. The present study was approved by the ethicalĬommittee of the Bone Marrow Transplantation Center of the FirstĪffiliated Hospital, Zhejiang University, and all participants Patients who received ASCT were retrospectively analyzed. Stem cell mobilization, the clinical data of 128 MM and lymphoma Study, in order to identify the factors influencing hematopoietic Patients at a high risk of mobilization failure. Improve PBSC mobilization, as well as to accurately identify Malignancies treated with ASCT and further studies are required to MM and lymphoma are the major hematologic Studies have reported precise changes in the CD34+ cell count
Hübelīlood CD34+ cells as a routine predictive indicator. Mobilization process, monitoring the mononuclear and CD34+ cellĬount in the peripheral blood enables the prediction of acquisitionĮfficiency, and helps to determine the timing of acquisition. PBSCs is simpler, and patients recover more quickly, thus resulting Compared with ASCT with bone marrow hematopoieticĬells, it is generally accepted that ASCT with PBSCs requires fewerĬells for infusion additionally, the collection procedure for Hematopoietic stem cells (PBSCs) are the stem cell sources forĪlmost all ASCTs. Efficient acquisition of autologous stemĬells is the premise of successful ASCT. Therapy, ASCT still results in the most favorable patient outcome Large number of targeted treatments have been used in clinical drug Progression-free survival (PFS) and overall survival (OS) times of ThisĬombination therapy has been proven to significantly improve the Myeloma (MM) and a number of different types of lymphoma. In the treatment of hematologic malignancies, including multiple Hematopoietic stem cell transplantation (ASCT) has been widely used High-dose chemotherapy combined with autologous
PBSC mobilization yielded sufficient CD34+ cell counts both in MM and lymphoma patients however, the failure rates were relatively high. In the present study, different factors influencing PBSC mobilization and collection in MM and lymphoma cases were identified. Univariate and multivariate statistical analysis revealed that negative factors for PBSC mobilization in patients with MM were lenalidomide treatment, multiple chemotherapies, incomplete disease remission and low‑level blood hemoglobin in patients with lymphoma, the negative factors were the histological disease type, incomplete disease remission, being beyond the first‑line of previous chemotherapy, multiple chemotherapies, chemotherapy with the HyperCVAD‑B mobilization scheme, high‑dose MTX/Ara‑c (methotrexate/cytarabine) treatment, prolonged administration of G‑CSF and low‑hematocrit levels. The yields of CD34+ cells per kilogram of patient body weight 2.0x106/kg or >5.0x106/kg were defined as a failure, a success or ideal mobilization, respectively. Autologous PBSCs were mobilized using granulocyte‑colony stimulating factor (G‑CSF) during chemotherapy, and collected using a continuous flow cell separation instrument. Clinical data from 128 patients, including 53 MM and 75 malignant lymphoma (7 Hodgkin's lymphoma and 68 non‑Hodgkin's lymphoma) cases were retrospectively analyzed. Factors affecting peripheral blood hematopoietic stem cell (PBSC) mobilization and collection were investigated in patients with multiple myeloma (MM) and lymphoma who were undergoing chemotherapy.
0 kommentar(er)
